TRIAL DETAIL
Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 05/01/2007 |
Age of Trial (yrs) 18 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
SGI-0470-01 |
|||
Sponsor: |
SuperGen Inc. |
|||
Patient Contact: |
SuperGen
Gil Fine, PhD
925-560-0100
gfine@supergen.com
Angelique Mittan, CLS
925-560-0100 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This information is from the second ClinicalTrials.gov entry for this trial. See also NCT00504205. |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
10460 N. 92nd Street, Suite 206 |
Scottsdale |
AZ |
85248 |
USA |
|
4319 Medical Dr. |
San Antonio |
TX |
78229 |
USA |